Ureklin for injection

Urinary kallidinogen is a proteolytic enzyme extracted from human urine that can convert kininogen into kinin and kallidin. In vitro studies have shown that urinary kallidin has a dilating effect on isolated arteries, inhibits platelet aggregation, and enhances red blood cell deformability and oxygen dissociation ability. Animal experiments have shown that intravenous injection of urinary kallidin can increase blood flow in the intervertebral, common carotid and femoral arteries of anesthetized dogs, and increase blood flow in the anesthetized hind limbs and muscles of rabbits. Injection of glass beads into the internal carotid artery of rabbits causes brain microvascular damage. Intravenous administration of urinary kallidin can dilate cerebral blood vessels, increase the hemoglobin content in cerebral blood, reduce the expansion of cerebral infarction area, improve the decreased glucose and oxygen uptake in brain tissue caused by infarction, improve glucose metabolism, and improve spontaneous cortical electroencephalogram abnormalities.

Human urinary kallikreinase is a glycoprotein composed of 238 amino acids extracted and purified from fresh human urine.

This product is a white freeze-dried block or powder, which is hygroscopic and easily soluble in water.

Mild to moderate acute thrombotic cerebral infarction

The medication should be started within 48 hours of onset. 0.15 PNA units each time, dissolved in 50ml or 100ml sodium chloride injection, intravenous drip for 30 minutes, once a day, 3 weeks as a course of treatment.

A total of 645 patients entered the Phase II and III clinical trials of urinary kallidinol for the treatment of acute cerebral infarction, of which 462 were in the trial group (urinary kallidinol group). There were 4 serious adverse events in the trial group, including 2 deaths (1 was a 75-year-old with right cerebellar hemisphere infarction and basal ganglia lacunar infarction, and the cause of death was determined to be cerebellar infarction complicated by brain herniation; the other was a 70-year-old with right fronto-parietal temporal infarction, and the cause of death was determined to be sudden cardiac death). It was judged to be unrelated to the study drug. In the other 2 cases, the first injection of the trial drug (both within 10 minutes of the start of medication) caused a sudden drop in blood pressure accompanied by impaired consciousness. After the drug was immediately stopped and pressor drugs were given, the blood pressure quickly recovered without adverse consequences, and it was determined to be related to the medication. A total of 9 important adverse events occurred in the Phase III clinical trial, of which 4 occurred in the infarct focus.

The acute phase of cerebral hemorrhage and other hemorrhagic diseases.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Refer to [Usage and Dosage].

1. Ureklin and angiotensin-converting enzyme inhibitors (ACEI) have a synergistic antihypertensive effect. Combination therapy may cause a sharp drop in blood pressure. 2. Ureklin has no synergistic antihypertensive effect with other antihypertensive drugs.

Keep sealed. Tentatively three years.

0.15PNA units/bottle

36 months

Techpool BIO-PHARMA Co., Ltd.

• Founded in:

  1993-03-25

• Address:

  No. 89, Gaopu Road, Tianhe Gaotang Science and Technology Industrial Park, Tianhe District, Guangzhou

• Tax NO.:

  91440101190490505C

• Registered Funds:

  100 million yuan

• Website:

  Log in to view

• Email:

  Log in to view